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Abstract
Retinitis pigmentosa (RP) is the most common inherited human eye disease resulting in night blindness and visual defects. It
is well known that the disease is caused by rod photoreceptor degeneration; however, it remains incurable, due to the
unavailability of disease-specific human photoreceptor cells for use in mechanistic studies and drug screening. We obtained
fibroblast cells from five RP patients with distinct mutations in the RP1, RP9, PRPH2 or RHO gene, and generated patient-
specific induced pluripotent stem (iPS) cells by ectopic expression of four key reprogramming factors. We differentiated the
iPS cells into rod photoreceptor cells, which had been lost in the patients, and found that they exhibited suitable
immunocytochemical features and electrophysiological properties. Interestingly, the number of the patient-derived rod cells
with distinct mutations decreased in vitro; cells derived from patients with a specific mutation expressed markers for
oxidation or endoplasmic reticulum stress, and exhibited different responses to vitamin E than had been observed in clinical
trials. Overall, patient-derived rod cells recapitulated the disease phenotype and expressed markers of cellular stresses. Our
results demonstrate that the use of patient-derived iPS cells will help to elucidate the pathogenic mechanisms caused by
genetic mutations in RP.
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Introduction
Retinitis pigmentosa (RP) leads inevitably to visual impairment
due to irreversible retinal degeneration, specifically of primary rod
photoreceptors. The condition causes night blindness and visual
field defects. The disease onset spans a wide range of ages, but RP
most often occurs in late life. There is no treatment that allows
patients to avoid deterioration of visual function. RP encompasses
a number of genetic subtypes, with more than 45 causative genes
and a large number of mutations identified thus far. The genetic
heterogeneity of RP suggests a diversity of disease mechanisms,
which remain largely unclear. Furthermore, for many of the RP
subtypes, no appropriate animal models are available. Although
large clinical trials have been conducted with a-tocopherol and b-
carotene, these studies found no statistically significant change of
visual function in RP patients [1,2]. The underlying mutations
causing disease in the patients tested in the clinical trials were not
revealed, and the variability of individual responses to these drugs
is unknown. One of the reasons why these clinical trials failed to
examine the effectiveness of drugs is that the effect of a drug may
be different between patients with different underlying mutations.
Induced pluripotent stem (iPS) cells reprogrammed from
somatic cells [3,4] have enabled us to easily generate patient-
derived terminally differentiated cells in vitro [5–7]. We have
successfully induced differentiation of photoreceptor cells from
both human embryonic stem (ES) cells [8] and iPS cells [9,10].
Modeling pathogenesis and treatment in vitro using patient iPS cell-
derived photoreceptors will elucidate disease mechanisms; cir-
cumvent problems related to differences among species that arise
when using animal models; decrease patient risk; and reduce the
cost of early-stage clinical trials. Here, we generated iPS cells from
RP patients with different mutations and demonstrated the
potential of patient-derived photoreceptors for disease modeling.
Materials and Methods
RP patients and genetic mutations
The protocol of this study adhered to the tenets of the
Declaration of Helsinki. The study was approved by the ethical
committees of the Institute of Biomedical Research and Innova-
tion Hospital and the RIKEN Center for Developmental Biology,
Japan. Written informed consent from all patients was obtained.
We selected five RP patients from four families whose disease-
causing mutations have been identified (Fig. 1A–D and Fig. S1).
Of the five RP patients in this study, three late-onset patients
carried the following mutations: 721Lfs722X in RP1, W316G in
PRPH2, and G188R in RHO. Two relatively early-onset patients
from the same family carried a H137L mutation in RP9, which we
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patients showed typical manifestations of RP (Tab. S1).
Peripheral blood obtained from patients was used for DNA
isolation. A comprehensive screening of disease-causing genes was
carried out as described previously [11]. For the RP9 mutation,
total RNA was isolated from fresh blood samples and iPS cells, and
synthesized cDNA was subjected to PCR and direct sequencing to
confirm whether the mutation was located in the RP9 gene or the
pseudo-RP9 gene (paralogous variant). Both fibroblast and iPS
cells were analyzed to re-confirm the identified mutation.
iPS cells generation
To generate iPS cells, retroviral transduction of Oct3/4, Sox2,
Klf4, and c-Myc into patient-derived fibroblast cells was carried
out as described previously [3]. Established iPS cell lines were
maintained on a feeder layer of mitomycin C-treated SNL cells (a
murine-derived fibroblast STO cell line expressing the neomycin-
resistance gene cassette and LIF) in a humidified atmosphere of
5% CO2 and 95% air at 37uC. Cells were maintained in DMEM-
F12 supplemented with 0.1 mM non-essential amino acids,
0.1 mM 2-mercaptoethanol, 2 mM L-glutamine, 20% KnockOut
Serum Replacement (KSR), and 4 ng/ml basic fibroblast growth
factor (Upstate Biotechnology).
Transgene quantification
To examine the copy number of transgenes integrated into the
host genome, DNA was isolated and quantitative detection of viral
transgenes was performed using real-time PCR. The endogenous
gene was used as a control. Before quantitative PCR, a standard
curve for each primer and/or probe set was determined using a set
of plasmid DNA dilutions. Taqman qPCR to detect integrated
OCT3/4, KLF4, and MYC was performed using 20 ml reactions
consisting of 10 ml TaqMan Master Mix with uracil N-glycosylase,
4.9 mM primers, 250 nM probe, and 1 ml of the DNA sample.
Quantification of viral SOX2 was assayed using SYBR Green.
Teratoma formation
Animal protocols were approved by the RIKEN Center for
Developmental Biology ethical committee (No. AH18-05). A total
of 10
7 trypsinized iPS cells were injected subcapsularly into the
testis of SCID mice (two mice per iPS cell line). Four weeks later,
the testis was fixed and sectioned for H&E staining.
Figure 1. iPS cells derived from RP patients. Mutations identified in patients K21 (RP1) (A), K11 and K10 (RP9) (B), P101 (PRPH2) (C), and P59
(RHO) (D). Patient-derived fibroblast cells (E) were reprogrammed into iPS cells (F). The iPS cells expressed SSEA-4 (G) and Nanog (H). A teratoma
formation test confirmed iPS cells’ ability to generate all three germ layers: endoderm (I), mesoderm (J) and ectoderm (K). Karyotype analysis (I). Scale
bars, 50 mm.
doi:10.1371/journal.pone.0017084.g001
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Cells were fixed with 4% paraformaldehyde for 15 min at 4uC
and then permeabilized with 0.3% Triton X-100 for 45 min. After
1 h blocking with 5% goat serum, cells were incubated with
primary antibodies overnight at 4uC and subsequently with
secondary antibodies for 1 h at room temperature. The primary
and second antibodies used are listed in Tab. S2.
Karyotype analysis
Karyotype analysis of the iPS cell chromosomes was carried out
using a standard G-band technique (300–400 band level).
Photoreceptor differentiation and drug testing
In vitro differentiation of rod photoreceptor cells was performed
as previously reported [8], but with a minor modification. To find
a KSR optimal for retinal differentiation, lot testing was conducted
before differentiation. iPS colonies were dissociated into clumps
with 0.25% trypsin and 0.1 mg/ml collagenase IV in PBS
containing 1 mM CaCl2 and 20% KSR. Feeder cells were
removed by incubation of the iPS cell suspension on a gelatin-
coated dish for 1 h. iPS clumps were moved to a non-adhesive
MPC-treated dish (NUNC) in maintenance medium for 3 days, in
20% KSR-containing differentiation medium (DMEM-12 supple-
mented with 0.1 mM non-essential amino acids, 0.1 mM 2-
mercaptoethanol, 2 mM L-glutamine) for 3 days, then in 15%
KSR-containing differentiation medium for 9 days, and finally in
10% KSR-containing medium for 6 days. Cells were treated with
Lefty-A and Dkk-1 during floating culture. At day 21, the cells
were plated en bloc on poly-D-lysine/laminin/fibronectin2coated
8-well culture slides (BD Biocoat) at a density of 15–20 aggregates/
cm
2. The cells were cultured in 10% KSR-containing differenti-
ation medium until day 60. Cells were further treated with
100 nM retinoic acid (Sigma) and 100 mM taurine (Sigma) in
photoreceptor differentiation medium (GMEM, 5% KSR,
0.1 mM non-essential amino acids, 0.1 mM 2-mercaptoethanol,
1 mM pyruvate, N2 supplement, and 50 units/ml penicillin,
20 mg/ml streptomycin). Differentiated cells from both normal
and patient iPS cells were treated with 100 mM a-tocopherol,
200 mM ascorbic acid and 1.6 mM b-carotene starting at
differentiation day 120. One week later, cells were fixed for
immunostaining.
Electrophysiological recording
Recombinant lentiviral vectors expressing GFP under the
control of the Nrl or RHO promoters were generated in HEK293t
cells (RIKEN Cell Bank), and differentiated cells were infected
with virus on day 90. Cells expressing GFP were targeted for patch
clamp recordings. Voltage-clamp recordings were performed with
12–15 MV glass electrodes. Signals were amplified using Multi-
clamp 700B amplifiers (Molecular Devices). The internal solution
was 135 mM K-gluconate, 10 mM HEPES, 3 mM KCl, 0.2 mM
EGTA, 2.5 mM MgCl2, 5 mM adenosine 59-triphosphate,
0.3 mM guanosine-59-triphosphate, 0.06 mM Alexa Fluor 594
(Molecular probes), adjusted to pH 7.6 with KOH. The retinal
cells were perfused with oxygen-bubbled external medium:
23 mM NaHCO3, 0.5 mM KH2PO4, 120 mM NaCl, 3.1 mM
KCl, 6 mM Glucose, 1 mM MgSO4, 2 mM CaCl2, and 0.004%
Phenol red. The medium was heated to 37uC with a temperature
controller (Warner Instruments).
Cell count and statistical analysis
Differentiated cells visualized with specific antibodies were
counted blindly by an independent observer. Data are expressed
as means 6 s.e.m. The statistical significance of differences was
determined by one-way ANOVA followed by Tukey’s test or
Dunnett’s test, or by two-way ANOVA followed by Bonferroni test
using the GraphPad Prizm software. Probability values less than
0.05 were considered significant.
Results
Generation of iPS cell lines from patients with RP
Mutations identified in the five patients were confirmed by bi-
directional sequencing (Fig. S1). Through genotyping of four
patients and two normal relatives in the RP9 family, we found the
H137L mutation in the RP9 gene co-segregated with the disease,
strongly indicating that the mutation is indeed the genetic cause of
the disease. We cultured fibroblasts from skin samples of these
patients on gelatin-coated dishes (Fig. 1E) and infected them with
retroviral vectors encoding OCT3/4 (also known as POU5F1),
SOX2, KLF4,a n dc-MYC, using a previously established method [3].
Each mutation was re-confirmed in both fibroblasts and iPS cells.
Established iPS colonies showed human embryonic stem cell-like
morphology (Fig. 1F and Fig. S3A) and expressed pluripotency
markers (Fig. 1C–D). We selected iPS cell lines for each patient
using multiple criteria. First, we excluded iPS cell lines in which
spontaneous differentiation occurred repeatedly during mainte-
nance (Fig. S3B). We chose iPS colonies that maintained
morphologies similar to those of human ES cells through more
than 10 passages. Second, we quantifiedthe transgene copynumber
and selected iPS cell lines with the fewest integrations, as the risk of
gene disruption through random insertion increases with the
number of transgenes (Fig. S4A–E). Third, in order to select iPS
cell lines with full pluripotency, we verified the ability to form
teratomas. Teratomas formed by injecting iPS colonies into the
testisinvivoshowedcontributionstoall threeembryonicgermlayers:
ectoderm, mesoderm, and endoderm (Fig. 1E–G). Finally,
karyotype analysis was carried out to examine the chromosome
integrity. The patient-iPS cells showed normal karyotypes after
extended passage, indicating chromosomal stability (Fig. 1H).
These results provide in vitro and in vivo functional proof of
pluripotency for RP patient-derived iPS cells.
Generation of patient-specific retinal photoreceptor
We previously demonstrated in vitro differentiation of retinal
photoreceptor cells from wild-type human ES [8] and iPS cells [9,10]
using a stepwise differentiation method known as serum-free culture
of embryoid body-like aggregates [12]. We first evaluated the
differentiation efficiency of three selected iPS cell lines of the five
patients (Fig. 2A). Retinal progenitor, photoreceptor precursor,
retinal pigment epithelium (RPE) and rod photoreceptor cells were
sequentially induced (Fig. 2B–K), consistent with our previous
studies [8–10,12]. All patient-derived iPS cell lines differentiated into
RPE cells that form ZO-1+ tight junctions on differentiation day 60,
with timing, morphology, and efficiency similar to that of wild-type
iPS cells (Fig. 2D–E; Fig. S5). Immature photoreceptors expressing
Crx and Recoverin (day ,60) were observed as clusters in the
colonies (Fig. S6A–B). The patient-iPS cells also differentiated into
blue Opsin+ or red/green Opsin+ cone photoreceptor cells (Fig. 2H
and data not shown). Immunostaining of Rhodopsin (a marker of
mature rod photoreceptors) revealed no Rhodopsin+ cells at
differentiation day 100 (data not shown). Rhodopsin+ cells appeared
at differentiation day 120 with a stable efficiency of the three
independent iPS cell lines from each patient (Fig. 2K,N and Fig.
S6C).Additionally,15.160.60% and 13.361.65% cellswerepositive
for Recoverin (a conventional marker for both rod, cone photore-
ceptors and cone bipolar cells)in K21- and K11-iPS cells,respectively
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(A) Experimental schema. (B) Neural retina progenitor cells (Pax6+Rx+) and RPE progenitor cells (Mitf+) were separated in the culture dish (C). Patient-
specific RPE cells exhibited hexagonal morphology and pigmentation (D) and expressed the tight junction marker ZO-1 (E). Photoreceptor cells were
positive for immature photoreceptor markers Crx and Recoverin on day 60 (F). Recoverin+ cells did not co-express Ki67, a proliferating cell marker (G).
Differentiation of rod photoreceptors (Rhodopsin+) and cone photoreceptors (Opsin+) from patient iPS cells (H). Rhodopsin + rod photoreceptors
induced from K21-iPS at day 120 (I). K11-derived rod photoreceptors were observed at day 120 (J). No Rhodopsin+ cells were detected, but
Recoverin+ cells were present at day 150(K). Induced rod photoreceptor cells (Crx+) labeled with lentiviral vectors encoding GFP driven by a rod
photoreceptor-specific promoter Nrl (L: Nrl-GFP) or Rhodopsin (M: Rho-GFP). Arrows indicate cells co-expressing Crx and GFP. (N) Whole-cell
recording of rod photoreceptor cell differentiated human iPS cells. Recorded cells expressed GFP under the control of the Rhodopsin promoter.
(O) Relationship between voltage and membrane current (i) produced a non-linear curve, suggesting that voltage-dependent channels exist in iPS
cell-derived rod photoreceptors Rec, Recoverin; Rho, Rhodopsin. Scale bars, 50 mm.
doi:10.1371/journal.pone.0017084.g002
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Furthermore, we confirmed rod induction by labeling with lentiviral
vectorsdrivingGFPfromtheRhodopsinandNrlpromoters,eitherof
which is specifically expressed in rod photoreceptors (Fig. 2L–M).
Whole-cell patch-clamp recording demonstrated that the rod
photoreceptor cell membrane contains voltage-dependent channels,
suggesting that differentiated patient-derived rod cells are electro-
physiologically functional (Fig. 2N–O). Meanwhile, the excluded iPS
cell lines (ones that showed spontaneous differentiation during
maintenance, or had a high copy number of transgenes), demon-
strated a significant diversity of differentiation (Fig. S7). Together,
these data show that patient-derived iPS cells can differentiate into
cells that exhibit many of the immunochemical and electrophysio-
logical features of mature rod photoreceptor cells.
Patient-specific rod cells undergo degeneration in vitro
As compared with normal iPS cells, there is no significant
difference in rod cell differentiation efficiency at day 120 in
K21(RP1)-, P101(PRPH2)-, and P59(RHO)-iPS cell lines (Fig. 3).
iPScellsfrombothK11(RP9)andK10(RP9)carriedaRP9mutation;
however, rod cell number was significantly lower than in normal iPS
cells (Fig.3). We asked whether early death of precursor cells leads to
a smaller number of mature rod photoreceptor cells. To determine
whether genetic mutations induce degeneration in photoreceptors
cellsin vitro, we extended the culture period and evaluated the number
of rod photoreceptors at day 150. In differentiated iPS cells from
patient K21(RP1) at day 150, the number of Rhodposin+ cells was
significantly decreased (Fig. 3). For the K11-iPS cells, no
Rhodposin+ cells were found at day 150 (Fig. 3). Importantly, some
K11-cells at day 150 were positive for Recoverin (10.361.99%) and
Crx, markers for the rod, cone photoreceptors, and/or bipolar cells
(Fig. 2K and data not shown), strongly suggesting that cone
photoreceptor and/or bipolar cells survived, whereas the rod
photoreceptors underwent degeneration in vitro.I na d d i t i o n ,w e
detectedcellspositiveforIslet1(amarkerforretinalamacrine,bipolar
and ganglion cells), again consistent with the survival of other types of
retinal cells (Fig. S6F). From these results, we concluded that mature
rod photoreceptors differentiated from patient iPS cells selectively
degenerate in an RP-specific manner in vitro.
Cellular stresses involved in patient-derived rod cells
We next asked how the patient-derived rod photoreceptors
degenerate. We evaluated apoptosis and cellular stresses in each
cell line at both day 100 and day 120, respectively. Interestingly, in
the RP9-iPS (K10 and K11) cells, a subset of Recoverin+ cells co-
expressed cytoplasmic 8-hydroxy-2’-deoxyguanosine (8-OHdG), a
major oxidative stress marker, indicating the presence of DNA
oxidation in RP9 patient-derived photoreceptors by differentiation
day 100 (Fig. 4A and Fig. S8). More caspase-3+ cells were
presented in the Crx+ photoreceptor cluster of RP9-iPS than in
those from other lines (Fig. 4C–D). After maturation of the rod
photoreceptors from RP9-iPS cells, Rhodopsin+ cells co-expressed
Acrolein, a marker of lipid oxidation (Fig. 4E), while no
Rhodopsin+/Acrolein+ cells were observed in iPS cells derived
from other patients carrying different mutations or in normal iPS
cells (Fig. 4F). This pattern was similar to the cases of 8-OHdG
and activated caspase-3. Thus, we conclude that oxidation is
involved in the RP9-rod photoreceptor degeneration.
In differentiated RHO-iPS (P59) cells, we found that Rhodopsin
proteins were localized in the cytoplasm (Fig. 4G), as determined
by immunostaining with anti-Rhodopsin antibody (Ret-P1). This
pattern is unlike the normal localization of Rhodopsin at the cell
membrane in photoreceptors derived from normal iPS or other
patient-derived iPS cells (Fig. 4H and data not shown). This result
suggests accumulation of unfolded Rhodopsin, as reported
previously in rhodopsin mutant mice cells [13]. We next examined
the possible involvement of endoplasmic reticulum (ER) stress in
RHO-iPS cell line degeneration. The Rhodopsin+ or Recoverin+
cells co-expressed immunoglobulin heavy-chain binding protein
(BiP) or C/EBP homologous protein (CHOP), two conventional
markers of endoplasmic reticulum (ER) stress, from day 120
(Fig. 4I,K and Fig. S9), while cells derived from control iPS or
other mutant iPS cells were negative for BiP and CHOP
(Fig. 4J,L). Taken together, these results demonstrate that ER
stress is involved in rod photoreceptors carrying a RHO mutation.
Drug evaluation in patient-specific rod cells
The antioxidant vitamins a-tocopherol, ascorbic acid, and b-
carotene have been tested in clinical trials as dietary therapies for
RP [2] and in another major retinal degenerative disease, age-
related macular degeneration [14]. Thus far, mostly due to the
lack of appropriate validation models, there has been no evidence
supporting the beneficial effects of these compounds on rod
photoreceptors. We therefore assessed the effects of these agents
on rod photoreceptors derived from patient iPS cells. In mouse
retinal culture, short-term treatment with a-tocopherol, ascorbic
acid and b-carotene at 100 mM, 200 mM and 1.6 mM, respective-
ly, exerted no significant toxic effects on rod photoreceptor cells
(Fig. S10). Since the differentiated rod photoreceptors underwent
degeneration after day 120, we treated the cells for 7 days with
these agents starting at day 120 (Fig. 2A). a-Tocopherol treatment
significantly increased the number of Rhodopsin+ cells in iPS cells
derived from K11- and K10-iPS with the RP9 mutation, while it
had no significant effects on iPS cells with the either the RP1,
PRPH2 or RHO mutation (Fig. 5). In contrast, neither ascorbic
acid nor b-carotene treatment had any effect on iPS cells of any
genotype (Fig. S11). We cannot currently explain the discrepancy
between the effects of these antioxidants. It has been reported that
under certain circumstances, anti-oxidants can act as ‘‘pro-
oxidants’’ [15]. Taken together, our results indicate that treatment
with a-tocopherol is beneficial to RP9-rod photoreceptor survival,
and causes different effects on Rhodposin+ cells derived from
different patients.
Figure 3. RP patient-derived rod photoreceptors undergo
degeneration in vitro. iPS cells were differentiated into Rhodopsin+
rod photoreceptors in serum-free culture of embryoid body-like
aggregates (SFEB culture). The percentages of Rhodopsin+ rod
photoreceptors were evaluated at both day 120 and day 150,
respectively. Data were from three independent iPS cell lines derived
from the patients. ANOVA followed by Dunnett’s test. * p,0.05;
***p,0.001. Values in the graphs are means and s.e.m.
doi:10.1371/journal.pone.0017084.g003
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By using patient-derived iPS cells and in vitro differentiation
technology, we have shown that RP9-retinitis pigmentosa is
involved, at least in part, in oxidative stress pathways; this has not
been reported previously in any animals or cell models.
Furthermore, we have demonstrated that the antioxidant a-
tocopherol exerts a beneficial effect on RP9-rod cells. Additionally,
we have clearly shown that rod photoreceptors derived from
patients with a RHO mutation are associated with ER stress; this is
Figure 4. Cellular stress in patient-derived rod photoreceptor cells. Oxidative stress and apoptosis in differentiated rod photoreceptor cells
derived from RP9-iPS (A,C,E) and RP1-iPS (B,D,F). (A) 8-OHdG, a marker for DNA oxidation, was found in K11- or K10-iPS2derived differentiated cells
(day 100), but not in K21-iPS (B). Arrow indicates a cell double-positive for 8-OHdG and Recoverin. (C) The number of activated Caspase-3+ cells was
greater in K11-iPS differentiation than in K21-iPS (D). From day 120, rod photoreceptor cells (Rhodopsin+) derived from RP9-iPS co-expressed the
oxidative stress marker Acrolein (E); whereas RP1-iPS derivatives did not (F). (G–L) Abnormal cellular localization of Rhodopsin proteins and
endoplasmic reticulum stress in RHO-iPS2derived rod photoreceptors. High magnification revealed cytoplasmic localization of Rhodopsin in rod
photoreceptor cells carrying a RHO mutation (G) and a normal localization in the cell membrane in K21 cells (H). Rod cells derived from RHO-iPS co-
expressed the ER stress markers BiP (I) and CHOP (K). K21-iPS2derived rod cells did not express BiP (J) or CHOP (L). Arrows indicate double-positive
cells. Rec, Recoverin; Rho, Rhodopsin. All scale bars are 50 mm except for G and H (20 mm).
doi:10.1371/journal.pone.0017084.g004
Figure 5. Disease modeling of patient-derived rod photoreceptor cells. a-Tocopherol treatment of patient-specific rod photoreceptors
yielded a significant beneficial effect in RP9 mutant cells. Two-way ANOVA Bonferroni post-test showed no significance in other group (n=3–8). Data
represent 1–2 selected iPS cell lines of each patient. ***p,0.001. Values in the graphs are means and s.e.m.
doi:10.1371/journal.pone.0017084.g005
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cells. These cell models will be very useful for disease mechanism
dissection and drug discovery. By screening several drugs that had
already been tested in RP patients, we have revealed that rod
photoreceptor cells derived from RP patients with different genetic
subtypes exhibit significant differences in drug responses. Among
the different types of antioxidants, a-tocopherol has either
beneficial or non-beneficial effects on diseased photoreceptors,
depending on the genetic mutation. This is the first report of the
utilization of iPS cells related to personalized medicine, which will
be helpful for routin clinical practice. Our results also provided
evidence that genetic diagnosis is essential for optimizing
personalized treatment for patients with retinal degenerative
diseases [11]. An important future study made possible by this
work is the screening of a compound library for drugs that could
be used to treat RP. Patient-derived iPS cells revealed differences
in pathogenesis and the efficacy of antioxidants among patients
with different disease-causing mutations. Although the microen-
vironment affects the pathogenesis of diseases, and in vitro
evaluation is not perfect, this study suggests that iPS cells could
be used to select between multiple available treatments, allowing
physicians to advise each patient individually. The weakness of our
method for disease modeling is that differentiation requires a long
period of time. Shortening the induction period and identifying
appropriate surface markers for rod cells will improve disease
modeling using patient-specific iPS cells.
In brief, we generated pluripotent stem cells from retinitis
pigmentosa patients and induced them into retinal cells.
Compared with normal cells, patient-derived rod cells simulated
the disease phenotype and exhibited different responses to specific
drugs. We found that patient-specific rod cells underwent
degeneration in vitro, which maybe related to different cellular
stresses. To our knowledge, this is the first report of disease
modeling of retinal degeneration using patient-derived iPS cells.
Supporting Information
Figure S1 Pedigrees of K21 (A), P59 (B), K10 and K11 (C).
Families of P59 (B) and K10 and K11 (C) show autosomal
dominant mode of inheritance. (C) Mutation analysis was
performed in four patients and two normal relatives in the RP9
family. The H137L mutation in RP9 gene was co-segregated with
the disease in the family. Closed symbols indicate individuals with
RP and open symbols indicate unaffected subjects. Question
marks indicate symptom unknown. The bars above the symbols
indicate examined subjects. Arrow, proband; slash, deceased.
(TIF)
Figure S2 Mutation in the RP9 gene. (A) Alignment of RP9
sequence and pseudo-gene shows the same nucleotide in the
mutated location. (B) Sequence chromatogram of cDNA sequence
demonstrates the c.410A.T (H137L) mutation in the RP9 gene,
instead of the paralogous variant in pseudo-gene which was
documented in RetNet (www.sph.uth.tmc.edu/retnet/disease.
htm).
(JPG)
Figure S3 Selection by colony morphology. (A) iPS colony
(K21S4) shows ES-like morphology. (B) Spontaneous differentia-
tion in the colony during maintenance (K21S14). Scale bars,
50 mm.
(TIF)
Figure S4 Quantification of transgene copy number.
Total copy number of four transgenes in the selected iPS lines.
Selected iPS cells with fewest integrations and two high copy
number lines used for in vitro differentiation.
(TIF)
Figure S5 Efficiency of RPE induction in patient-iPS
cells. RPE production of the five patient-iPS cells showed no
significant differences (n=4). Data represent the percentage of
RPE area at differentiation day 60. One-way ANOVA followed by
Dunnett’s test. Values are mean and s.e.m.
(TIF)
Figure S6 Induced retinal cells from patient iPS cells
(K21S4). Crx+ photoreceptor precursor cells present in the cell
cluster on differentiation day 60 (A). Crx+ cells co-expressed
Recoverin, indicating differentiation into photoreceptor cells (B).
Rhodopsin+ cells had a long process at day 150 (C). In the
differentiated cells, we also observed cells positive of PKCa (a
marker for bipolar cells) (D). Cells positive for Math5 and Brn3b
(markers for ganglion progenitor or ganglion cells (day 60) (E).
Cells positive for Islet-1 (a marker for amacrine, bipolar and
ganglion cells) (F). Scale bars, 50 mm (A, D, E, and F); 20 mm( B
and C).
(TIF)
Figure S7 Differentiation of the patient-iPS cells. iPS
colony was cut into uniform sized pieces (A) and subjected to a
floating culture (P59M8, day 20) (B). RPE (pigmented) and
recoverin+ (green) cells were efficiently induced (P59M8, day 60)
(C). (D) An excluded iPS line, P59M16, with high number
transgenes showed a striking lentoid formation during the floating
culture (day 20). Scale bars, 50 mm.
(TIF)
Figure S8 Oxidative stress in photoreceptor cells with
the RP9 mutation (K11). (A) Recoverin, (B) 8-OHdG, (C)
Recoverin/8-OHdG, (D) Recoverin/8-OHdG/DNA. Arrows
indicate cells with weak Recoverin signal positive for 8-OHdG;
Arrowheads represent cells with strong Recoverin signal positive
for 8-OHdG; Asterisks represent Recoverin+ cells negative for 8-
OHdG. Scale bar, 50 mm.
(JPG)
Figure S9 ER stress in photoreceptor cells with the
RHO mutation (P59). (A) CHOP, (B) Recoverin, (C)
Recoverin/CHOP, (D) Recoverin/CHOP/DNA. Arrows indicate
cells with weak Recoverin signals positive for CHOP in nuclei;
Arrowheads represent cells with strong Recoverin signals positive
for CHOP; Asterisks represent Recoverin+ cells negative for
CHOP. Scale bar, 50 mm.
(JPG)
Figure S10 Toxicity testing of the antioxidants in
murine retina-derived rod photoreceptor cells. Primary
culture of mouse retinal cells treated with 100 mM a-tocopherol,
200 mM ascorbic acid or 1.6 mM b-carotene for 24 hours and the
rod photoreceptors were counted using flow cytometry. Value
represents the ratio of treated-rod photoreceptors compared with
control cells. n=4. One-way ANOVA followed by Dunnett’s test.
Values are mean and s.e.m. NS, not significant.
(JPG)
Figure S11 Differentiated rod cells from normal and
patient iPS cells treated with 200 mM ascorbic acid or
1.6 mM b-carotene did not show statistically significant
differences. Two-way ANOVA Bonferroni post-test. Values are
mean and s.e.m.
(JPG)
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